Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595329 | 1.00 | KDM4E (0.40) | KDM4EPOLBNR1H2ALOX15HTT | |
| SCHEMBL26099585 | 0.87 | L3MBTL1 (0.39) | KDM4EPOLBNR1H2HTTGABRA5 | |
| SCHEMBL3028022 | 0.72 | HTR6 (0.38) | KDM4ENR1H2ALOX15HTTGABRG2 | |
| SCHEMBL3248285 | 0.72 | L3MBTL1 (0.43) | KDM4EPOLBDTYMKL3MBTL1GPR119 | |
| SCHEMBL30220573 | 0.71 | MAPK14 (0.35) | KDM4ENR1H2GABRG2GABRB3GABRA5 | |
| SCHEMBL29640143 | 0.71 | POLB (0.41) | KDM4EPOLBNR1H2DTYMKGPR119 | |
| SCHEMBL2361004 | 0.71 | POLB (0.41) | KDM4EPOLBNR1H2DTYMKGPR119 | |
| SCHEMBL27873298 | 0.71 | CHRM2 (0.45) | KDM4EPOLBNR1H2GABRG2GABRB3 | |
| SCHEMBL26097320 | 0.70 | ALDH1A1 (0.36) | KDM4ENR1H2HTTGABRA5L3MBTL1 | |
| SCHEMBL3030930 | 0.70 | GABRG2 (0.34) | NR1H2GABRG2GABRB3GABRA5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717734-B2 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| US-20190119269-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717734-B2 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | IDO1, IDO2, INMT | KDM4E 359/4885POLB 2471/4885NR1H2 2578/4885 |
| US-20190119269-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | KDM4E 359/4885POLB 2471/4885NR1H2 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.